Hence, the pre-existing anticancer activities of patients with high risk scores may be restrained by the higher level of tumour infiltrated macrophages (M2) and the over-expression of many inhibitory immune checkpoints (such as CD274 and LAG3). This evidence concerns the gene CD274 and neoplasm.